Biotherapeutics Company TrueBinding and Bioinformatics Platform PipeBio Announce Ongoing Collaboration

TrueBinding, a clinical stage biotherapeutic company and PipeBio, a bioinformatics cloud platform company, are excited to announce their joint effort in bioinformatics analyses supporting TrueBinding’s research and development efforts. The collaboration brings advanced analytics and storage capabilities to TrueBinding’s therapeutic antibody discovery pipeline that is aimed to find c**** for diseases with unmet medical needs, including neurodegenerative diseases (AD, PD, ALS), stroke, metabolic diseases and oncology.

As part of the collaboration, PipeBio has helped TrueBinding implement a fully integrated, single-click, repeatable hybridoma analysis workflow for large scale NGS data. The fully automated workflow runs on PipeBio’s bioinformatics cloud platform and enables analysis of hundreds of single-cells from hybridomas which has helped TrueBinding speed up and scale up analysis on-demand to successfully find desired candidate sequences throughout different antibody discovery campaigns.

Recommended AI News: AB Tasty and Mixpanel Announce Two New Integrations to Accelerate Digital Product Innovation

“We use PipeBio’s platform for everything from sequence analysis and data visualization to storage of NGS data and hit-picked sequences all from our hybridoma sequencing work. The transition to PipeBio’s platform was seamless thanks to the continued support from the PipeBio team.” – Parastu Nejad, Research Associate, TrueBinding

TrueBinding’s need for a powerful and flexible bioinformatics platform stems from the large amounts of data generated from single-cell experiments in multiple discovery programs. PipeBio’s bioinformatics cloud handles everything from data storage and computation to tools for the final data analysis, constituting the fully integrated solution.

Recommended AI News: Darktrace Adds Early Warning System to Antigena Email

“The discovery research on novel treatments for neurodegenerative diseases coming from TrueBinding’s lab is truly inspiring and we are excited to be able to contribute to this work” – Jannick Bendtsen, CEO, PipeBio

With its proprietary Truebinding™ platform, TrueBinding has to date discovered several novel drug targets and developed monoclonal antibody drugs to combat disease areas with unmet therapeutic needs. The company’s most prominent program, TB006, a humanized monoclonal antibody targeting Galectin-3 for treating both Alzheimer’s disease and stroke, is currently in Phase II trials.

Recommended AI News: Pega Launches Pega Process Extender for Salesforce Lightning on Salesforce App Exchange and Pega Marketplace

[To share your insights with us, please write to sghosh@martechseries.com]